Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859680 | 0.84 | MEN1 (0.50) | CYP1A2CYP3A4CYP2D6SMN1; SMN2USP2 | |
| SCHEMBL7748824 | 0.79 | CYP1A2 (0.45) | CYP1A2CYP3A4CYP2D6SMN1; SMN2USP2 | |
| SCHEMBL9039161 | 0.78 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6SMN1; SMN2USP2 | |
| SCHEMBL8034260 | 0.75 | SMN1; SMN2 (0.49) | CYP1A2CYP3A4CYP2D6SMN1; SMN2USP2 | |
| SCHEMBL7837246 | 0.75 | SMN1; SMN2 (0.56) | CYP1A2SMN1; SMN2LMNAALDH3A1GAA | |
| SCHEMBL4873241 | 0.75 | NOD1 (0.66) | CYP1A2CYP2D6SMN1; SMN2ALDH3A1GAA | |
| SCHEMBL2792751 | 0.74 | LMNA (0.61) | CYP2D6SMN1; SMN2USP2LMNAPKM | |
| SCHEMBL16376073 | 0.70 | TDP1 (0.58) | SMN1; SMN2LMNAGAATSHRTP53 | |
| SCHEMBL2794427 | 0.69 | APEX1 (0.51) | CYP1A2CYP3A4CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL7100805 | 0.67 | ALDH3A1 (0.61) | USP2LMNAALDH3A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030140-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-6908936-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2005-02-17 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2003-07-24 | — | — | US | disclosed |
| US-6506738-B1 | Treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection. | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-14 | — | — | US | disclosed |
| WO-2002026228-A1 | BENZIMIDAZOLONE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | CYP1A2 1840/4885CYP3A4 174/4885CYP2D6 897/4885 |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | CYP1A2 1840/4885CYP3A4 174/4885CYP2D6 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.